

SB 192 -2 STAFF MEASURE SUMMARY

Senate Committee On Health Care

Prepared By: Daniel Dietz, LPRO Analyst

Meeting Dates: 4/3

WHAT THE MEASURE DOES:

Directs the Department of Consumer and Business Services to study access to prescription drugs.

REVENUE: No revenue impact

FISCAL: Has minimal fiscal impact

ISSUES DISCUSSED:

EFFECT OF AMENDMENT:

-2 Replaces the measure. Directs pharmacy benefit managers (PBMs) to file a report with the Department of Consumer and Business Services (DCBS) to include the aggregated dollar amount of rebates, fees, price protection payments, and any other payments the PBM received from drug manufacturers. Specifies reporting requirements for patient assistance programs funded by drug manufacturers. Specifies reporting requirements for health insurance plans. Increases number of members on the prescription drug advisory board from five to eight members.

BACKGROUND:

In 2018, the Legislative Assembly passed the Prescription Drug Price Transparency Act (House Bill 4005), which requires pharmaceutical manufacturers and insurers to report specified prescription drug cost and price information. In 2021, the Legislative Assembly established Oregon's Prescription Drug Affordability Board (PDAB) and directed it to review and report on the cost and affordability of different categories of prescription drugs.

Senate Bill 844 directs the PDAB to provide recommendations for legislative changes necessary to make prescription drug products more affordable ([Link](#) to PDAB's 2022 Report for the Legislature). Among recommendations, the PDAB recommends annual reporting of the aggregated dollar amount of rebates, fees, and any other payments to Pharmacy Benefit Managers from drug manufacturers.

Senate Bill 192 directs pharmacy benefit managers (PBMs) to file a report with the Department of Consumer and Business Services (DCBS) to include the aggregated dollar amount of rebates, fees, price protection payments, and any other payments the PBM received from drug manufacturers.